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OBJECTIVE: To determine neonatal and maternal outcomes 
stratified by asthma severity during pregnancy by using 
the 1993 National Asthma Education Program Working 
Group on Asthma and Pregnancy definitions of asthma 
severity. The primary hypothesis was that moderate or 
severe asthmatics would have an increased incidence of 
delivery at <32 weeks of gestation compared with nonas­
thmatic controls.
METHODS: This was a multicenter, prospective, observa­
tional cohort study conducted over 4 years at 16 university 
hospital centers. Asthma severity was defined according to 
the National Asthma Education Program Working Group 
on Asthma and Pregnancy classification and modified to
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include medication requirements. This study had 80% power 
to detect a 2- to 3-fold increase in delivery lessthan32 weeks of 
gestation among the cohort with the moderate or severe 
asthma compared with controls. Secondary outcome mea­
sures included obstetrical and neonatal outcomes.
RESULTS: The final analysis included 881 nonasthmatic 
controls, 873 with mild asthma, 814 with moderate, and 52 
with severe asthma. There were no significant differences 
in the rates of preterm delivery less than 32 weeks (moder­
ate or severe 3.0%, mild 3.4%, controls 3.3%; P = .873) or 
less than 37 weeks of gestation. There were no significant 
differences for neonatal outcomes except discharge diagno­
sis of neonatal sepsis among the mild group compared with 
controls, adjusted odds ratio 2.9, 95% confidence interval 
1.2, 6.8. There were no significant differences for maternal 
complications except for an increase in overall cesarean 
delivery rate among the moderate-or-severe group com­
pared with controls (adjusted odds ratio 1.4, 95% confi­
dence interval 1.1, 1.8).
CONCLUSION: Asthma was not associated with a significant 
increase in preterm delivery or other adverse perinatal 
outcomes other than a discharge diagnosis of neonatal 
sepsis. Cesarean delivery rate was increased among the 
cohort with moderate or severe asthma. (Obstet Gynecol 
2004;103:5-12. © 2004 by The American College of Ob­
stetricians and Gynecologists.)
LEVEL OF EVIDENCE: 11-2
Asthma is probably the most common potentially seri­
ous medical complication of pregnancy. A recent study 
suggests that nearly 6% of pregnant women have 
asthma, and the most recent asthma surveillance data 
suggest that approximately 9% of the U.S. population 
report a physician diagnosis of asthma during their life­
time.1-3 In general, the prevalence and morbidity from 
asthma are increasing.1,3
There have been few large prospective studies of 
asthma during pregnancy. M oreover, previous studies
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have a num ber of methodological inadequacies, includ­
ing low power; poor control for confounders; little infor­
mation regarding asthma severity, management, or con­
trol; and time frames not reflective of current 
management. Existing studies on the effects of asthma on 
pregnancy outcomes have had inconsistent results in 
regard to perinatal mortality, prematurity, low birth 
weight, neonatal hypoxia, cesarean delivery, hem or­
rhage, and preeclampsia.3-18 Asthma has been associ­
ated with preterm  delivery in some,4 ~9 but not all stud­
ies.3’10 ~16 Prem aturity is a leading cause of perinatal 
m ortality and long-term neurological morbidity in chil­
dren, with very early preterm  births (less than 32 weeks 
of gestation) accounting for most of the morbidity and 
m ortality .19 Perlow et al8 in 1992 reported a case-control 
study of 130 controls and 81 women with asthma, 31 of 
whom  required long-term oral corticosteroids and 50 
who had nonsteroid m edication-dependent asthma. 
T hey  found a 7.7-fold increase of preterm delivery less 
than 37 weeks and a 4-fold increase of deliveries less than 
32 weeks of gestation among those with asthma com­
pared with controls.
In 1993, under the auspices of the National Asthma 
Education Program of the National, Heart, Lung, and 
Blood Institute, a working group on asthma and preg­
nancy defined mild, moderate, and severe asthma ac­
cording to symptoms and pulm onary function criteria in 
untreated patients.20 T he relationship between National 
Asthma Education Program severity classification and 
pregnancy outcomes has not been reported 3-18
T he 1993 National Asthma Education Program guide­
lines did not discuss classification of asthma severity for 
women who were already receiving medications for their 
asthm a.20 W e previously reported asthma morbidity 
among the women in this study21 and modified National 
Asthma Education Program asthma severity criteria to 
include medication use. W om en with moderate asthma 
solely on the basis of requiring daily asthma medications 
had significantly more asthma exacerbations than those 
with mild asthma, but they did not have significantly 
more exacerbations than those with moderate asthma 
based on symptoms and measurements of forced expira­
tory volume of air expired in 1 second (FEV1). W om en 
with severe asthma solely on the basis of requiring daily 
oral corticosteroids had significantly more exacerbations 
than those with moderate asthma, but they did not have 
significantly more exacerbations than those with severe 
asthma based on FEV1 .21
T he purpose of this study was to determine pregnancy 
outcomes stratified by asthma severity in a contempo­
rary  cohort of asthmatic women. T he prim ary objective 
was to determine the frequency of preterm delivery at 
less than 32 weeks of gestation and other perinatal
outcomes among those with asthma compared with non­
asthmatic controls.
METHODS
This was a prospective observational cohort study that 
was sponsored by the National Institute of Child Health 
and H um an Development and the National, Heart, 
Lung, and Blood Institute. T he study was conducted at 
16 centers of the Maternal-Fetal Medicine Units Net­
work of the National Institute of Child Health and 
H um an Development. T he target enrollment was 900 
women with mild asthma, 900 with moderate or severe 
(moderate-severe) asthma, and 900 control participants. 
Smoking status is an important determinant of both 
asthma morbidity and perinatal outcome. T o  avoid a 
disproportion of frequency of the smokers in the three 
cohorts, the control and mild-asthma cohorts were pro­
spectively balanced in terms of the proportions of smok­
ing status (any in the past week) with the moderate- 
severe cohort. Controls were also prospectively 
balanced for proportion of African-American ethnicity 
with the moderate-severe cohort. Smoking status and 
asthma severity were determined upon enrollment. Re­
cruitment began in December 1994 and ended in M arch 
1999. Case finding was by questioning all obstetric pa­
tients about ever having physician-diagnosed asthma. 
Informed, written consent was obtained from all partic­
ipants, and each institution’s local Institutional Review 
Board approved the study. Exclusion criteria at enroll­
m ent included the following: known multiple gestation, 
intrauterine fetal demise, major congenital abnormali­
ties, active pulm onary disease other than asthma, inabil­
ity to schedule an ultrasound for gestational age confir­
mation, gestational age 26 weeks or more at intake, or 
participation in the asthma randomized clinical trial or 
other interventional studies. In addition to these exclu­
sion criteria, any woman who had ever had a physician 
diagnosis of asthma was excluded from the control 
group.
W e collected demographic, social, and medical infor­
mation, including ethnicity, age, smoking status (any in 
the previous week), prepregnancy weight, miscarriage/ 
abortion, history of preterm  delivery, insurance type, 
education, marital status, and chronic hypertension de­
fined as either systolic more than 140 mm Hg or diastolic 
blood pressure more than 90 mm H g on at least two 
occasions 4 or more hours apart when not pregnant or at 
less than 20 weeks of gestation or if the patient was on an 
antihypertensive medication when not pregnant or at 
less than 20 weeks of gestation. Spirometry (more than 4 
hours postbronchodilator) was performed on partici­
pants with asthma at enrollment. M easurements of
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Classification 
of asthma Criteria
Mild AH of the following:
Asthma symptoms in the prior 6 months 
Asthma symptoms fewer than 8 days in prior
4 weeks (except with URI)
FEV1 >  80% predicted 
Not taking daily asthma medications* 
Moderate Any of the following:
Asthma symptoms on 8 or more days during 
the prior 4 weeks not attributable to a URI 
FEV; 60-79% predicted 
Use of one or more daily asthma 
medications*
Severe Any of the following:
FEV! <  60% predicted 
Use of daily or every other day oral 
corticosteroids for 4 weeks prior to 
enrollment
FEV1 = forced expiratory volume of air expired in f second, mea 
sured at the time of enrollment >  4 hours post bronchodilator.
* Daily medications included 2 puffs per day of inhaled |8 agonist, 
cromolyn, nedocromil, inhaled steroids, or 4 puffs per day of 
ipratropium or f dose per day of theophylline. Patients on regular 
oral corticosteroids were classified as severe irrespective of other 
criteria.
FEV 1 were made while the patient was standing after a 
maximal inspiration. T o  standardize spirometry tech­
niques, all centers used Collins Stead-Well (Braintree, 
MA) dry-seal volume displacement spirometers, and all 
research nurses underw ent a training and quality review 
program.
O n each m onthly study visit, an FEV1 was obtained, 
and information regarding symptom frequency, asthma 
medication use, and the occurrence of asthma exacerba­
tions was recorded. An exacerbation was defined as 
asthma symptoms (cough, dyspnea, or wheezing) severe 
enough to result in a medical intervention, including 
hospitalization, unscheduled visits (physician office or 
emergency department), and/or treatment with oral cor­
ticosteroids among subjects who were not already taking 
regular oral corticosteroids.
T he classification of asthma severity was determined 
upon enrollment in the study. As we previously report­
ed21 and for the purposes of the current study, the 
National Asthma Education Program definitions of 
asthma severity were modified to include medication 
use T able 1)- Daily medication was defined as at least
2 puffs per day of inhaled /3-agonist, cromolyn, 
nedocromil, or inhaled steroids, or at least 4 puffs per 
day inhaled ipratropium, or at least f dose per day of 
theophylline. Regular oral corticosteroid use was defined 
as daily or every other day dosing for at least 4 weeks 
before entry in the study.
Table 1. C lass ifica tion  o f Asthm a Severity T he gestational age at the time of randomization was 
determined from the last menstrual period if it correlated 
with the first ultrasound. Dating was based upon first 
ultrasound if the last menstrual period estimate varied by 
more than 7 days from the ultrasound gestational age 
estimate if the first ultrasound was performed less than 20 
weeks of gestation or more than f 4 days if the first ultra­
sound was performed at or after 20 weeks of gestation.
T he prim ary hypothesis was that the cohort with 
moderate-severe asthma would have an increased inci­
dence of delivery at less than 32 weeks of gestation 
compared with nonasthmatic controls.8 From previous 
studies, we estimated that the rate of preterm  delivery at 
less than 32 weeks would be between 2% and 3°/o.22 W e 
felt that a 2- to 3-fold increase of preterm delivery among 
the moderate-severe cohort would be plausible and clin­
ically relevant. W e estimated that a sample size of 900 
per group would be sufficient, with power of at least 
80%, 2-sided type I error of 0.05, and allowing for a loss 
to follow-up rate of as much as f 0%.
Secondary analyses included the incidence of gesta­
tional diabetes, preeclampsia, prem ature preterm  rup­
ture of membranes, induced for fetal indication, cliorio- 
amnionitis, oligohydramnios, cesarean delivery for fetal 
distress, total cesarean delivery, wheezing during labor, 
gestational age, preterm  delivery (less than 37 weeks), 
labor duration, postpartum  hemorrhage (more than 500 
mL for vaginal delivery or more than f,000 mL for 
cesarean delivery), birth weight, small for gestational age 
(less than fOth percentile, Brenner et al23), perinatal 
mortality, hyaline membrane disease, bronchopulm o­
nary dysplasia, discharge diagnosis of neonatal sepsis, 
major congenital anomalies, patent ductus arteriosis, 
neonatal intensive care unit admission, intraventricular 
hemorrhage, necrotizing enterocolitis, and transient 
tachypnea of newborn. These data were obtained at 
postpartum  chart reviews.
T he Biostatistics Center of George W ashington U ni­
versity maintained the data and performed the statistical 
analysis using SAS 8.2 (SAS Institute, Cary, NC) statis­
tical software. T he data were analyzed by using 
Kruskal-W allis for continuous variables and x 2 test and 
logistic regression analysis for dichotomous variables. 
Logistic regression covariates included asthma severity, 
previous preterm  delivery, smoking status, African 
American versus other race, previous elective or sponta­
neous abortion, type of insurance, and minimum of high 
school education. For sparse outcomes, a reduced co- 
variate set consisting of the first 4 covariates was used. 
Body mass index and oral corticosteroid use were also 
covariates for the model for gestational diabetes. Logistic 
regression results are reported as odds ratios and 95%
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Table 2. D em ograph ic and B ase line  In fo rm a tion
Moderate-severe 




(N = 881) Overall P
Race .002
African American 447(51.6) 518 (59.3) 458 (52.0)*
Caucasian 325 (37.5) 269 (30.8) 324 (36.8)
Hispanic 77 (8.9) 78 (8.9) 74 (8.4)
Other 17 (2.0) 8 (0.9) 25 (2.8)
Age (y) _ 24.2 ± 6.1 22.4 ± 5.3 24.8 ± 6.1 <  .001
Mean gestational age at enrollment (wk) 18.9 ± 4.8 18.1 ± 4.9 19.8 ± 4.3 <  .001
Previous preterm delivery 142 (16.4) 111 (12.7) 136 (15.4) .081
Previous miscarriages/abortions 363 (41.9) 323 (37.0) 345 (39.2) .110
At least 12 years of schooling 522 (60.3) 509 (58.3) 584 (66.4) .002
Smoked at enrollment 162 (18.7) 164 (18.8) 166 (18.8) .998
Chronic hypertension 46 (5.3) 23 (2.6) 39 (4.4) .017
Mean prepregnancy body mass index 27.9 ± 7.9 27.3 ± 7.6 26.5 ± 7.1 .002
Married 300 (34.6) 213 (24.4) 343 (38.9) <  .001
Insurance .001
Government 680 (78.5) 702 (80.4) 644 (73.1)
Private 136 (15.7) 100 (11.4) 164 (18.6)
None 50 (5.8) 71 (8.1) 73 (8.3)
Data presented as ./V(%) or mean ±  standard deviation.
* Not significant compared with moderate severe cohort, P =  .764.
confidence intervals (95% CIs) with the control group as 
the referent. Significance was defined at P <  .05 without 
correction for multiple comparisons.
RESULTS
A total of 2,171 patients with asthma were asked to enroll 
in the study; 359 (16.5%) declined participation. W e 
recruited 906 women with mild asthma, 906 with m od­
erate-severe asthma, and 928 controls. O ne hundred 
twenty (4.4%) patients were lost to follow-up. Com pared 
with the cohort remaining in the study, women lost to 
follow-up were significantly different with respect to age 
(24 ±  6 years versus 22 ±  5 years; P  =  .002), weeks of 
gestational age at enrollment (19 ±  5 weeks versus 18 ± 
5 weeks; P  =  .006), and government insurance (77.3% 
versus 84.2%; P  =  .014). Losses to follow-up did not 
affect the relative balance of smoking or ethnicity among 
the 3 cohorts. T he final analysis included 881 controls, 
873 with mild asthma, and 866 with moderate-severe 
asthma. O f the moderate-severe cohort, 52 (6.0%) were 
classified as having severe asthma. Demographic and 
baseline information and length of follow-up by initial 
severity group are presented in Table 2. There were 
significant differences in ethnicity, age, level of educa­
tion, body mass index, marital status, chronic hyperten­
sion, and type of insurance. T he mean gestational age at 
study entry was 19.3 ±  4.7 weeks. W om en with m oder­
ate-severe asthma were treated with the following medi­
cations during the 4 weeks before enrollment: inhaled 
/3-agonist (n =  377, 41.6%), inhaled corticosteroids (n =
194,21.4%), theophylline (n =  54, 6.0%), oral corticoste­
roids (n =  18,2.0%), inhaled ipratropium (n =  19,2.1%), 
inhaled cromolyn or inhaled nedocromil (n =  15,1.7%), 
and oral /3-agonist (n =  11, 1.2%). Patients could be on 
more than one medication. During this study, 4 women 
were intubated for asthma exacerbations, but there were 
no maternal deaths.
Patients with mild asthma had an asthma exacerbation 
rate of 12.6% (n =  110), and asthma hospitalization rate 
of 2.3% (n =  20) .21 Those with moderate asthma had an 
exacerbation rate of 25.7% (n =  209) and hospitalization 
rate of 6.8% (n =  55). Severe asthmatics had exacerba­
tion and hospitalization rates of 51.9% (n =  27) and 
26.9% (n =  14), respectively. During this study, 23% of 
women had an improvement in asthma severity, and 
30.3% had an increase of asthma severity.21
Among women with asthma, we found no significant 
differences in the rates of preterm  delivery less than 32 
weeks or delivery less than 37 weeks (Table 3). Neither 
asthma nor asthma severity (moderate-severe or mild) 
was significantly related to preterm delivery by logistic 
regression analysis. There were no significant differences 
for antepartum, delivery or postpartum  outcomes com­
pared with controls except increased cesarean delivery 
rate among the moderate-severe group. W heezing dur­
ing labor was significantly associated with asthma sever­
ity. T here were no significant differences in neonatal 
outcomes (Table 4), except for a discharge diagnosis of 
neonatal sepsis among the mild group compared with 
controls.
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Table 3. A n te p a rtu m , Delivery, and Postpartum  O utcom es
Moderate- 
severe 
















Delivery <  32 weeks 26 (3.0) 30 (3.4) 29 (3.3) .873 0.9 (0.5, 1.6) 1.0 (0.6, 1.8)
Delivery <  37 weeks 137 (15.8) 141 (16.1) 139 (15.8) .973 1.0 (0.8, 1.3) 1.0 (0.8, 1.3)
Gestational diabetes 57 (6.6) 29 (3.3) 42 (4.8) .007 1.4 (0.9, 2.1) 0.7 (0.4, 1.1)
Preeclampsia 107 (12.4) 106 (12.2) 98 (11.2) .703 1.1 (0.8, 1.5) 1.1 (0.8, 1.5)
Preterm premature rupture of 100 (11.6) 113 (13.0) 98 (11.2) .484 1.0 (0.8, 1.4) 1.2 (0.9, 1.6)
membranes
Induced for fetal indication 21 (2.4) 23 (2.6) 15(1.7) .386 1.4 (0.7, 2.8) 1.6 (0.8, 3.0)
Chorioamnionitis 44 (5.1) 59 (6.8) 44 (5.0) .197 1.0 (0.7, 1.6) 1.4 (0.9, 2.1)
Oligohydramnios 71 (8.2) 44 (5.1) 52 (5.9) .021 1.4 (1.0, 2.1) 0.8 (0.6, 1.3)
Cesarean delivery 203 (23.4) 160 (18.3) 160 (18.2) .007 1.4 (1.1, 1.7)* 1.0 (0.8, 1.3)
Cesarean delivery for fetal distress 35 (4.0) 35 (4.0) 35 (4.0) .997 1.0 (0.6, 1.6) 1.0 (0.6, 1.6)
Wheezing during labor 195 (22.7) 116 (13.4) 3 (0.3) <.001
Gestational age at delivery (wk) 38.5 ± 3.1 38.3 ± 3.7 38.3 ± 3.6 .950
Mean hours of labor 12.1 ± 9.2 12.9 ± 12.6 11.7 ±9.4 .181
Postpartum hemorrhage 60 (7.5) 63 (7.8) 44 (5.3) .091 1.5 (1.0, 2.2) 1.5 (1.0, 2.2)
OR = odds ratio; Cl = confidence interval.
Data presented as ,/Y’(%j or mean ± standard deviation.
* Logistic regr ession adjusted OR = 1.4 (95% Cl 1.1, 1.8).
Based on univariate analysis indicating significance, diabetes and delivery at less than 37 weeks of gestation
we performed a post hoc logistic regression analysis for remained si.gnificantly increased compared to controls
gestational diabetes, oligohydramnios, and cesarean de­ by adjusted odds ratio.
livery with severe asthma considered as a separate cate­
gory (Table 5). W e also included preterm  delivery and
small for gestational age because they have been in­ IJIbUUbblUN
creased among women who received oral corticosteroids Asthma was not associated with an increase in preterm
treatment of asthma during pregnancy .8:16 Gestational delivery at less than 32 weeks of gestation. W e chose
Table 4. Neonatal Outcomes
Moderate-severe Mild versus
versus controls controls
Moderate- [unadjusted OR [unadjusted OR
severe Mild Control Overall P " (95% Cl)] " (95% Cl)]
Birth weight (g) 3146 ± 667 3116 ± 699 3160 ± 706 0.291
Small for gestational age 60 (7.1) 59 (6.9) 51 (5.9) 0.579 1.2 (0.8, 1.8) 1.2 (0.8, 1.7)
Perinatal mortality 4 (0.5) 3 (0.3) 4 (0.5) 0.935 1.0 (0.2, 4.1) 0.7 (0.2, 3.4)
Hyaline membrane disease 18 (2.1) 21 (2.5) 13 (1.5) 0.365 1.4 (0.7, 2.9) 1.6 (0.8, 3.3)
Bronchopulmonary disease 8 (0.9) 6 (0.7) 2 (0.2) 0.165 4.1 (0.9, 19.3) 3.0 (0.6, 15.1)
Discharge diagnosis of neonatal 14 (1.7) 20 (2.3) 7 (0.8) 0.048 2.0 (0.8, 5.1) 2.9 (1.2, 7.0)*
sepsis
Congenital anomaly 36 (4.2) 33 (3.9) 34 (3.9) 0.919 1.1 (0.7, 1.7) 1.0 (0.6, 1.6)
Patent ductus arteriosus 7 (0.8) 6 (0.7) 3 (0.4) 0.429 2.4 (0.6, 9.2) 2.0 (0.5, 8.1)
Neonatal intensive care unit 147 (17.3) 152 (17.8) 133 (15.4) 0.379 1.1 (0.9, 1.5) 1.2 (0.9, 1.5)
admission
Intraventricular hemorrhage 1 (0.1) 7 (0.9) 4 (0.5) 0.099 0.2 (0.0, 2.3) 1.8 (0.5, 6.1)
Necrotizing enterocolitis 3 (0.3) 4 (0.5) 3 (0.3) 0.928 1.0 (0.2, 5.0) 1.3 (0.3, 6.0)
Transient tachypnea of 34 (4.0) 37 (4.3) 35 (4.0) 0.934 1.0 (0.6, 1.6) 1.1 (0.7, 1.7)
newborn
OR = odds ratio; Cl =  confidence interval.
Data presented as ,/Y’(%j or mean ±  standard deviation.
* Logistic regression adjusted OR = 2.9 (95% Cl 1.2, 6 .8)
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Table5. Logistic Regression Analysis for Severe Asthma Cohort Compared With Controls (N =  52)
Severe asthma 
[N (%)]
Unadjusted odds ratios 
(95% Cl)
Adjusted odds ratios 
(95% Cl)
Gestational diabetes 8 (15.4) 3.6 (1.6, 8.2) 3.0 (1.2, 7.8)
Oligohydramnios 6 (11.5) 2.1 (0.8, 5.1) 2.1 (0.9, 5.3)
Cesarean delivery 14 (26.9) 1.7 (0.9, 3.1) 1.6 (0.8, 3.1)
Delivery <  32 weeks 3 (5.8) 1.8 (0.5, 6.1) 1.6 (0.5, 5.5)
Delivery <  37 weeks 16 (30.8) 2.4 (1.3, 4.4) 2.2 (1.2, 4.2)
Small for gestational age 5 (9.8) 1.7 (0.7, 4.5) 1.6 (0.6, 4.4)
Discharge diagnosis of neonatal sepsis 2 (3.9) 5.0 (1.0, 24.7) 4.6 (0.9, 22.8)
Cl =  confidence interval.
Adjusted odds ratio covariates: previous preterm delivery, smoking status, African American versus other. Body mass index was also included 
in the model for gestational diabetes.
severe prem aturity as our prim ary outcome for several 
reasons. T he association of prem aturity and asthma is 
biologically plausible; both are characterized by chronic 
processes that are mediated in part by increased inflam­
m atory cytokines and increased smooth muscle reactiv­
ity. Preterm delivery at less than 32 weeks of gestation is 
clinically important, accounts for most of the perinatal 
m orbidity and mortality due to prem aturity ,19 and was 
reported to be increased among asthmatics receiving 
regular medications.8 There have been inconsistent find­
ings of an increased risk of prem aturity among women 
with asthm a.3-16 W e found an increased frequency of 
delivery at less than 37 weeks of gestation limited to the 
subset (n =  52) with severe asthma. This finding should 
be interpreted with caution; we could not control for the 
potential confounding effects of oral corticosteroid use 
because we used the need for oral corticosteroids as part 
of our definition to classify severe asthma. A large retro­
spective database study of 36,985 asthmatic patients did 
find an increased incidence of preterm births less than 37 
weeks; the incidence of preterm  births at less than 32 
weeks was not reported .9 T he largest prospective studies 
have not found a significant association of preterm  birth 
and asthma.10,14
O ther than increased frequencies of cesarean delivery 
among patients with moderate-severe asthma, discharge 
diagnosis of neonatal sepsis among those with mild 
asthma, and gestational diabetes and delivery less than 
37 weeks among the subset with severe asthma, we did 
not find increased perinatal or obstetrical morbidity com­
pared with controls. Because a discharge diagnosis of 
neonatal sepsis was found only among the cohort with 
mild asthma, the clinical importance of this outcome is 
not clear; this finding m aybe related to type 1 error. O ur 
findings are generally reassuring, despite a relatively 
high prevalence of asthma morbidity. After enrollment, 
27.3% of women in the moderate-severe cohort had 
asthma exacerbations, and 8% of these required hospi­
talization.21
A potential explanation for the inconsistencies among 
previous studies regarding the effect of asthma on obstet­
rical and neonatal outcomes may include the fact that 
most studies of asthma during pregnancy did not attempt 
to classify asthma severity. Classification of asthma se­
verity has important clinical implications with respect to 
asthma morbidity and tailoring optimal treatment regi­
m ens.1'20 Failure to classify severity may result in sub- 
optimal asthma control, thereby increasing risks for 
adverse maternal or neonatal outcomes. Oral corticoste­
roid treatment per se may confound maternal and neo­
natal outcomes. Some positive findings of our study and 
previous studies m aybe due to chance. In general, larger 
prospective studies have tended to find fewer significant 
adverse associations.10,14 O ur study has the strengths of 
being large, multicentered, prospective, stratified by 
asthma severity; including high-quality spirometry; and 
controlling for confounders, such as African-American 
ethnicity and smoking status.
T he prospective nature of this study may have led to 
better surveillance and treatment. T he low prevalence of 
adverse obstetrical and perinatal outcomes may have in 
part been the result of dissemination of the 1993 Na­
tional Asthma Education Program guidelines for treating 
asthma during pregnancy. These include 4 integral com­
ponents of asthma management, including using objec­
tive measures of pulm onary function, mitigating asthma 
triggers, patient education, and pharmacological man­
agement tailored for asthma severity with anti-inflamma­
tory therapy for moderate or severe asthm a.20 This was 
an observational study in which our investigators were 
not mandated to follow National Asthma Education 
Program  guidelines. However, they were familiar with 
the guidelines, and this study was conducted in parallel 
with a prospective randomized clinical trial in which all 
patients were managed using these guidelines. Aspects of 
asthma management, including medications, pulm onary 
function, compliance, and other outcomes, will be re­
ported in future articles.
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In 1997, the National Asthma Education Program 
published the Expert Panel Report II, in which the 
definitions of asthma severity were modified to include 
mild persistent asthma; however, these recommenda­
tions were not specific to pregnancy .1 Based on the new 
classification, our moderate cohort would include sub­
jects with both mild persistent and moderate persistent 
asthma.
O ur study has several im portant limitations. Because 
this was an observational study, the management of 
asthma was not standardized. T he diagnosis of asthma 
was attained primarily by eliciting a history of physician- 
diagnosed asthma, although this has been found to be a 
valid definition in epidemiological studies.24 Control 
participants were not rigorously evaluated for absence of 
asthma. W e did not take into account possible changes in 
asthma severity before enrollment in the study. O ur 
enrolled population was heavily weighted toward single 
mothers and enriched for African Americans and those 
with subsidized insurance. This likely reflects the urban 
centers that make up the Maternal-Fetal Medicine Units 
network. However, because asthma is m ore common 
and more severe in African Americans2 and more severe 
in patients with lower socioeconomic status,20'26 this is 
an important population to study. This study controlled 
for confounding factors, such as ethnicity and type of 
insurance, and had a large sample size and wide geo­
graphic representation; these strengths should increase 
the generalizability of our reassuring findings to other 
populations. However, one should be cautious about 
inferring the generalizability of our results in our partic­
ipants with severe asthma because of the relatively small 
size of this cohort in our study.
In conclusion, we had excellent maternal and perinatal 
outcomes despite a high frequency of asthma exacerba­
tions. These findings do not contradict the possibility 
that suboptimal control of asthma during pregnancy is 
associated with increased risk to the m other or baby.
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